TQB Stock Overview
Operates as a biotherapeutic research and technology company in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ImmunoPrecise Antibodies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$2.70 |
| 52 Week Low | US$0.85 |
| Beta | 0.26 |
| 11 Month Change | -5.56% |
| 3 Month Change | -32.00% |
| 1 Year Change | -67.05% |
| 33 Year Change | -81.91% |
| 5 Year Change | -61.54% |
| Change since IPO | -78.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| TQB | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.9% | 0.8% |
| 1Y | -67.1% | -12.7% | 6.1% |
Return vs Industry: TQB underperformed the German Life Sciences industry which returned -12.7% over the past year.
Return vs Market: TQB underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| TQB volatility | |
|---|---|
| TQB Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: TQB's share price has been volatile over the past 3 months.
Volatility Over Time: TQB's weekly volatility has decreased from 18% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 102 | Jennifer Bath | www.ipatherapeutics.com |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.
ImmunoPrecise Antibodies Ltd. Fundamentals Summary
| TQB fundamental statistics | |
|---|---|
| Market cap | €24.28m |
| Earnings (TTM) | -€9.65m |
| Revenue (TTM) | €16.03m |
1.5x
P/S Ratio-2.5x
P/E RatioIs TQB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TQB income statement (TTM) | |
|---|---|
| Revenue | CA$23.68m |
| Cost of Revenue | CA$11.39m |
| Gross Profit | CA$12.29m |
| Other Expenses | CA$26.55m |
| Earnings | -CA$14.26m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 51.88% |
| Net Profit Margin | -60.22% |
| Debt/Equity Ratio | 0% |
How did TQB perform over the long term?
See historical performance and comparison